# Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

> **NCT02991638** · PHASE3 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 62 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Indolent B-cell Lymphomas
- Chronic Hepatitis B
- Lymphoma, Small Lymphocytic
- Mantle-Cell Lymphoma
- Waldenstrom's Macroglobulinaemia
- Follicular Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02991638
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-01
- **Primary completion:** 2020-12
- **Final completion:** 2021-06
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2018-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991638, "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02991638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*